Put this in your pipe and smoke it........ get ready for that re-rate because this is where some of your dollars have been spent.
"TRXE-009-1 demonstrated broad cytotoxic activity across a large panel of cell lines and was particularly active against kidney (RCC), liver (HCC), head and neck cancer, lung cancer, sarcoma, prostate cancer, osteosarcoma, and neuroblastoma. Further, TRXE-009-1 combined synergistically with two targeted agents used extensively in the clinical treatment of RCC patients. Cleaved caspase 3/7 and G2/M arrest were strongly associated with TRXE-009-1 activity.
NRT Price at posting:
6.7¢ Sentiment: Buy Disclosure: Held